Giving hope to those affected
by secondary breast cancer

Research. Support. Education.
Donate M2C Shop Newsletter

UK Clinical Trial Registry

This registry lists all of the clinical trials that are currently actively recruiting secondary breast cancer patients in the UK.

Currently, patients and healthcare professionals have to search many different databases, such as clinicaltrials.gov, NIHR Be Part of Research or Cancer Research UK, to see what trials might be available. These databases use different search algorithms and the outcome of searches can be different and very time-consuming. This registry is intended as a “one stop shop” for UK secondary breast cancer clinical trials.

Clinical Trials for Secondary (Metastatic) Breast Cancer

The registry is divided into different categories based on the medical classification of secondary breast cancer. You can select a category to see a list of available trials and click on the study links to find the eligibility criteria. If you are unsure of your subtype, please speak to your clinical team. You can read more about the subtypes and receptors for breast cancer here. 

Next steps

If you are interested in trials, it is important to have a conversation with your clinical team and people around you who can support you. At Make 2nds Count, we offer an impartial and confidential Patient Trials Advocate (PTA) service for those interested in finding out more about clinical trials. Book an appointment with our friendly team of specialist nurses today.

Please see the Footnotes for Healthcare Professionals at the bottom of this page to learn how this registry is compiled and why it was developed. 

Jump to category:

ER+ or HR+ & HER2-

For patients who are oestrogen receptor positive, hormone receptor positive and HER2 (human epidermal growth factor receptor 2) negative.

A Study of SGN-B7H4V in Advanced Solid Tumors

Phase 1, advanced solid tumor: ER+ or HR+ & HER2- or TNBC

More info (clinicaltrials.gov)

Recruiting now in:

  • London

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Phase 3 trial for patients with HR+ HER2- metastatic breast cancer who have experienced disease progression after CDK4/6 inhibitor therapy

More info (clinicaltrials.gov)

Recruiting now in:

  • London

Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP

Phase 2, Patients with HR-positive, HER negative tumors or triple negative tumors

More info (clinicaltrials.gov)

Recruiting now in:

  • Edinburgh
  • Gillingham
  • Glasgow
  • Leeds
  • Swansea
  • Taunton

CAPItello-292: Capivasertib + CDK4/​6i + Fulvestrant for Advanced/​Metastatic HR+/​HER2- Breast Cancer (CAPItello-292)

Phase 1b/3 trial for metastatic HR+/HER2- breast cancer. Patients must be eligible for fulvestrant therapy and at least one of the following: palbociclib, ribociclib, or abemaciclib, as per local investigator assessment

More info (clinicaltrials.gov)

Recruiting now in:

  • Guildford
  • London
  • Londonderry (NI)
  • Taunton
  • York

CONCEPT: Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer

Phase 2, ER+ or HR+ & HER2- or ER- & HER2- (TNBC)

More info (clinicaltrials.gov)

Recruiting now in:

  • Bath
  • Blackburn
  • Bristol
  • Cardiff
  • Exeter
  • London
  • Newcastle
  • Nottingham
  • Plymouth
  • Taunton
  • Truro
  • Worcester

CYCAD-1: A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

First In Human, Phase I/IIa trial for ER+ HER2- advanced breast cancer patients

More info (classic.clinicaltrials.gov)

Recruiting now in:

  • Cambridge
  • London
  • Manchester

D4 Choline Breast PET/CT: Investigation of Changes in Tumour Choline Metabolism in Estrogen-receptor Positive / HER2 Negative Breast Cancer Patients Treated With CDK4/6 Inhibitors and Endocrine Therapy

Observational imaging study

More info (clinicaltrials.gov)

Recruiting now in:

  • London

DYNASTY-Breast02: A Study of DB-1303/​BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer

Phase 3 trial for HR+, HER2-low patients (defined as [IHC]2+/[ISH]- & IHC 1+) with disease progression after two lines of hormone therapy or within 6 months hormone therapy with a CDK4/6 inhibitor

More info (clinicaltrials.gov)

Recruiting now in:

  • London
  • Manchester
  • Truro

ELECTRA: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer

Phase 1b/2: Patients with brain metastases that are ER+ or HR+ & HER2- who have had at least one endocrine therapy, up to two chemotherapy regimens and up to two prior CDK 4/6 inhibitors, not including abemaciclib

More info (clinicaltrials.gov)

Recruiting now in:

  • Liverpool
  • London
  • Manchester

ELUCIDATE: Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors

Phase 1 & 2, advanced solid tumor study. Patients must be HR+ and HER2- and have experienced disease progression with prior treatment that included a CD4/CDK6 inhibitor

More info (clinicaltrials.gov)

Recruiting now in:

  • Glasgow
  • London
  • Manchester
  • Newcastle
  • Oxford

evERA Breast Cancer: A Study Evaluating the Efficacy & Safety of Giredestrant Plus Everolimus Compared With Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Metastatic Breast Cancer

Phase 3, prior endocrine therapy in combination with cyclin-dependent kinase 4/6 inhibitors

More info (clinicaltrials.gov)

Recruiting now in:

  • Dorset
  • London
  • Manchester
  • Nottingham

FAIM: Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

Phase 2, HR+/HER2- metastatic breast cancer & previously treated with no more than one prior line of chemotherapy for advanced disease

CRUK plain English summary (cancerresearchuk.org)

More info (clinicaltrials.gov)

Recruiting now in:

  • Cambridge
  • Edinburgh
  • Glasgow
  • London
  • Manchester
  • Nottingham
  • Truro

INAVO121: A Study Evaluating the Efficacy & Safety of Inavolisib + Fulvestrant Compared With Alpelisib + Fulvestrant in Participants With HR+, HER2-, PIK3CA Mutated, Locally Advanced / Metastatic Breast Cancer Post CDK4/​6i & Endocrine Combination Therapy

Phase 3: Patients who are ER+ or HR+ & HER2- and have a PIK3CA mutation & have progressed during or after CDK4/6 Inhibitor & Endocrine Combination Therapy

More info (clinicaltrials.gov)

Recruiting now in:

  • Basingstoke
  • Dumfries
  • Edinburgh
  • Harlow
  • Livingston
  • London
  • Maidstone
  • Northwood
  • Oxford
  • Preston
  • Winchester

JEWEL-101: Study of XB002 in Subjects With Solid Tumors

Phase 1, Metastatic Solid Tumors - metastatic breast cancer patients must be TNBC or ER+/HR+ & HER2-

More info (clinicaltrials.gov)

Recruiting now in:

  • Cardiff
  • Glasgow
  • Leicester
  • London
  • Newcastle

KORTUC Phase II: Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer

Phase 2, Breast metastases should be well controlled or oligometastatic & radical/high dose palliative radiotherapy required for lifetime control of local morbidities

CRUK plain English summary (cancerresearchuk.org)

More info (clinicaltrials.gov)

Recruiting now in:

  • Cambridge
  • Glasgow
  • Manchester
  • Stoke-on-trent
  • Sutton
  • Truro

MK-2870-010: A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/​HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

Phase 3 trial for HR+/HER2- metastatic breast cancer patients who have disease progression on one or more lines of endocrine therapy, with one in combination with a CDK4/6 inhibitor in the metastatic setting

CRUK plain English summary (cancerresearchuk.org)

More info (clinicaltrials.gov)

Recruiting now in:

  • London
  • Truro

Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Expanded Access for ER+ HER2- metastatic breast cancer

More info (clinicaltrials.gov)

Recruiting now in:

  • Cambridge
  • Newcastle
  • Radlett

NeoRay: [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake

Phase 1/2a: Tumor must be HR+ with ER > 10% of nuclei stain & HER-2 negative including HER-2 low and no standard therapy is available

More info (clinicaltrials.gov)

Recruiting now in:

OPERA-01: OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/​HER2- Advanced Breast Cancer

Phase 3 trial for ER+/HER2- metastatic breast cancer patients who have disease progression on one or more lines of endocrine therapy, with one in combination with a CDK4/6 inhibitor in the metastatic setting

More info (clinicaltrials.gov)

Recruiting now in:

  • London

Phase 1/​2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/​HER2-/​ER+ Breast Cancer

Phase 1/​2, Metastatic Androgen Receptor Positive (AR+)/​HER2-/​ER+ Breast Cancer, where no conventional therapy is available

More info (clinicaltrials.gov)

Recruiting now in:

  • Liverpool
  • London
  • Manchester

SERENA-6: Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression

Phase 3, ER+ & HER2- & ESR1m+

More info (clinicaltrials.gov)

Recruiting now in:

  • Blackpool
  • Cambridge
  • London
  • Manchester
  • Nottingham
  • Portsmouth
  • Sheffield
  • Sutton
  • Taunton

Study of INCB123667 in Subjects With Advanced Solid Tumors

advanced solid tumor HR+ & HER2- or TNBC

More info (clinicaltrials.gov)

Recruiting now in:

  • London
  • Newcastle

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i)

Phase 1, either: HR+ & HER2- or HR+ & HER2+

More info (clinicaltrials.gov)

Recruiting now in:

  • Edinburgh
  • London
  • Manchester

SUMIT-ELA: A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/​HER2-negative Breast Cancer

Phase 1b/2: Recieved prior AI in combination with a CDK4/6i as the last therapy

More info (clinicaltrials.gov)

Recruiting now in:

  • Belfast
  • Manchester
  • Oxford

VELA: Study of BLU-222 in Advanced Solid Tumors

Phase 1/2 trial for advanced solid tumors including metastatic HR+ HER2- breast cancer that has progressed following CDK4/6 inhibitor treatment

More info (clinicaltrials.gov)

Recruiting now in:

  • London

HER2+

For patients who are HER2 (human epidermal growth factor receptor 2) positive.

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

Phase 1, HER2+ advanced solid tumors that have no authorized or effective therapy available, or for patients for whom such therapies are considered inappropriate by the Investigator

More info (clinicaltrials.gov)

Recruiting now in:

  • Edinburgh
  • Sutton

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Phase 3 trial for PIK3CA-Mutated HER2+ Metastatic Breast Cancer. Patients will be excluded if they had systemic non-hormonal anti-cancer therapy for metastatic HER2+ breast cancer prior to initiation of induction therapy

More info (clinicaltrials.gov)

Recruiting now in:

  • Blackpool
  • Colchester
  • Northwood
  • Nottingham
  • Oxford

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Phase 1, Cohort 1: HER2+ Cohort 2: HER2-low

More info (clinicaltrials.gov)

Recruiting now in:

  • London
  • Manchester
  • Sutton

DYNASTY-Breast02: A Study of DB-1303/​BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer

Phase 3 trial for HR+, HER2-low patients (defined as [IHC]2+/[ISH]- & IHC 1+) with disease progression after two lines of hormone therapy or within 6 months hormone therapy with a CDK4/6 inhibitor

More info (clinicaltrials.gov)

Recruiting now in:

  • London
  • Manchester
  • Truro

heredERA Breast Cancer: A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer

Phase 3, HR+ & HER2+

CRUK plain English summary (cancerresearchuk.org)

More info (clinicaltrials.gov)

Recruiting now in:

  • Bangor
  • Bath
  • Blackpool
  • Cornwall
  • London
  • Maidstone
  • Nottingham
  • Preston
  • Rhyl
  • Stockton-on-Tees
  • Swansea

KORTUC Phase II: Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer

Phase 2, Breast metastases should be well controlled or oligometastatic & radical/high dose palliative radiotherapy required for lifetime control of local morbidities

CRUK plain English summary (cancerresearchuk.org)

More info (clinicaltrials.gov)

Recruiting now in:

  • Cambridge
  • Glasgow
  • Manchester
  • Stoke-on-trent
  • Sutton
  • Truro

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i)

Phase 1, either: HR+ & HER2- or HR+ & HER2+

More info (clinicaltrials.gov)

Recruiting now in:

  • Edinburgh
  • London
  • Manchester

HER2-

For patients who are HER2 (human epidermal growth factor receptor 2) negative.

A Study of SGN-B6A in Advanced Solid Tumors

Phase 1, advanced solid tumor HER2-

More info (clinicaltrials.gov)

Recruiting now in:

  • London
  • Sutton

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Phase 1 & 2, advanced solid tumor: HER2- & BRCA mutation OR TNBC with no BRCA mutation

More info (clinicaltrials.gov)

Recruiting now in:

  • Cambridge
  • London
  • Oxford
  • Sutton
  • Withington

CERTIS1: Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Advanced solid tumor HER2- & mutation in one of: BRCA, PALB2, RAD51C, or RAD51D

More info (clinicaltrials.gov)

Recruiting now in:

  • Glasgow
  • London
  • Newcastle

KORTUC Phase II: Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer

Phase 2, Breast metastases should be well controlled or oligometastatic & radical/high dose palliative radiotherapy required for lifetime control of local morbidities

CRUK plain English summary (cancerresearchuk.org)

More info (clinicaltrials.gov)

Recruiting now in:

  • Cambridge
  • Glasgow
  • Manchester
  • Stoke-on-trent
  • Sutton
  • Truro

TNBC

For patients who have Triple Negative Breast Cancer (TNBC) and are therefore oestrogen receptor negative, hormone receptor negative and HER2 (human epidermal growth factor receptor 2) negative.

A Study of NX-1607 in Adults With Advanced Malignancies

Phase 1, advanced solid tumor TNBC

More info (clinicaltrials.gov)

Recruiting now in:

  • Cambridge
  • Glasgow
  • London
  • Manchester
  • Newcastle
  • Oxford
  • Sutton

A Study of SGN-B7H4V in Advanced Solid Tumors

Phase 1, advanced solid tumor: ER+ or HR+ & HER2- or TNBC

More info (clinicaltrials.gov)

Recruiting now in:

  • London

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Advanced solid tumor TNBC

More info (clinicaltrials.gov)

Recruiting now in:

  • London
  • Manchester

Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP

Phase 2, Patients with HR-positive, HER negative tumors or triple negative tumors

More info (clinicaltrials.gov)

Recruiting now in:

  • Edinburgh
  • Gillingham
  • Glasgow
  • Leeds
  • Swansea
  • Taunton

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Phase 1 & 2, advanced solid tumor: HER2- & BRCA mutation OR TNBC with no BRCA mutation

More info (clinicaltrials.gov)

Recruiting now in:

  • Cambridge
  • London
  • Oxford
  • Sutton
  • Withington

ASCENT-03: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer

Phase 3, metastatic untreated TNBC

More info (clinicaltrials.gov)

Recruiting now in:

  • Cheltenham
  • Glasgow
  • Leeds
  • London

ASCENT-04: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Phase 3, TNBC & tumors express programmed cell death ligand 1 (PD-L1)

More info (clinicaltrials.gov)

Recruiting now in:

  • Edinburgh
  • Glasgow
  • Leeds
  • London
  • Nottingham

ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab

Phase 1, advanced solid tumor TNBC

More info (clinicaltrials.gov)

Recruiting now in:

  • Sutton

CONCEPT: Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer

Phase 2, ER+ or HR+ & HER2- or ER- & HER2- (TNBC)

More info (clinicaltrials.gov)

Recruiting now in:

  • Bath
  • Blackburn
  • Bristol
  • Cardiff
  • Exeter
  • London
  • Newcastle
  • Nottingham
  • Plymouth
  • Taunton
  • Truro
  • Worcester

CURATE: TT-702 in Patients With Advanced Solid Tumours

Phase 1 & 2, advanced solid tumor TNBC

More info (clinicaltrials.gov)

Recruiting now in:

  • London
  • Manchester
  • Southampton

FORTITUDE-301: A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Phase 1, advanced solid tumor TNBC & FGFR2b Overexpression

More info (clinicaltrials.gov)

Recruiting now in:

  • Manchester
  • Sheffield

HMBD-001 in Advanced HER3 Positive Solid Tumours

Phase 1 & 2, advanced solid HER3+ tumors, including TNBC

CRUK plain English summary (cancerresearchuk.org)

More info (clinicaltrials.gov)

Recruiting now in:

  • London
  • Oxford

JEWEL-101: Study of XB002 in Subjects With Solid Tumors

Phase 1, Metastatic Solid Tumors - metastatic breast cancer patients must be TNBC or ER+/HR+ & HER2-

More info (clinicaltrials.gov)

Recruiting now in:

  • Cardiff
  • Glasgow
  • Leicester
  • London
  • Newcastle

KORTUC Phase II: Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer

Phase 2, Breast metastases should be well controlled or oligometastatic & radical/high dose palliative radiotherapy required for lifetime control of local morbidities

CRUK plain English summary (cancerresearchuk.org)

More info (clinicaltrials.gov)

Recruiting now in:

  • Cambridge
  • Glasgow
  • Manchester
  • Stoke-on-trent
  • Sutton
  • Truro

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Phase Ib/II, TNBC

More info (clinicaltrials.gov)

Recruiting now in:

  • Birmingham
  • London
  • Manchester

PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

Phase 1, AR+ TNBC

More info (clinicaltrials.gov)

Recruiting now in:

  • London
  • Manchester
  • Nottingham
  • Sheffield

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Phase 2, for patients with metastatic TNBC who have received one prior systemic therapy in the metastatic setting (chemotherapy or immunotherapy) and radiographic disease progression has been documented

More info (clinicaltrials.gov)

Recruiting now in:

  • London

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Phase 1 & 2, advanced solid tumor TNBC

More info (clinicaltrials.gov)

Recruiting now in:

  • Cambridge
  • Leeds
  • London
  • Manchester
  • Newcastle

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumors Malignancies

Phase 1 & 2, advanced solid tumor TNBC & Nectin-4 expression

More info (clinicaltrials.gov)

Recruiting now in:

  • London
  • Manchester

Study of INCB123667 in Subjects With Advanced Solid Tumors

advanced solid tumor HR+ & HER2- or TNBC

More info (clinicaltrials.gov)

Recruiting now in:

  • London
  • Newcastle

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Phase 1 advanced solid tumor study. Patients must have received, and then progressed, relapsed, or been intolerant to, or ineligible for, at least 1 standard treatment regimen in the advanced or metastatic setting

More info (clinicaltrials.gov)

Recruiting now in:

  • Birmingham
  • Glasgow
  • London
  • Oxford
  • Southampton

The first-in-human trial of MDX-124 in patients with advanced cancer

Phase 1 First in Human, TNBC and solid tumor must overexpress ANXA1

More info (isrctn.com)

Recruiting now in:

  • Edinburgh
  • Liverpool
  • Oxford

TROPION-Breast05: A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic TNBC

Phase 3, PD-L1 positive TNBC

CRUK plain English summary (cancerresearchuk.org)

More info (clinicaltrials.gov)

Recruiting now in:

  • Cardiff
  • Leicester
  • Liverpool
  • London
  • Sutton

Solid Tumour Studies

Studies which typically investigate many solid, late stage (i.e., advanced) cancer types within one research study, including secondary breast cancer.

A first in human study to investigate the safety and tolerability of CV6-168 in combination with anti-cancer treatments in patients with advanced cancer

Phase 1/2a, advanced solid tumor study. First in human study in which patients of many different metastatic cancer types will be recruited. Patients must have failed at least one standard therapy

More info (isrctn.com)

Recruiting now in:

  • Belfast
  • Glasgow
  • Newcastle
  • Sutton

A First-in-human Study to Learn How Safe the Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors

Phase 1, advanced solid tumor first in human study. All solid tumors are being recruited in the dose expansion cohort.

More info (clinicaltrials.gov)

Recruiting now in:

  • Newcastle
  • Oxford
  • Sutton

A modular, multi-part, multi-arm, open-label, phase I/II study to evaluate the safety and tolerability of GRWD5769 alone and in combination with anticancer treatments in patients with solid malignancies

Phase 1 advanced solid tumor study. For solid tumors that are not considered appropriate for further standard treatment or progressive disease after at least 12 weeks of prior anti-PD-1 or an or anti-PD-L1 mAb therapy

More info (isrctn.com)

Recruiting now in:

  • Edinburgh
  • London
  • Manchester

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

Phase 1, Part A of study is dose escalation for advanced solid tumors

More info (clinicaltrials.gov)

Recruiting now in:

  • Cambridge
  • Glasgow
  • Sutton

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

Phase 1, HER2+ advanced solid tumors that have no authorized or effective therapy available, or for patients for whom such therapies are considered inappropriate by the Investigator

More info (clinicaltrials.gov)

Recruiting now in:

  • Edinburgh
  • Sutton

A Phase 1/​2 Study to Investigate CRB-701 in Solid Tumors

Phase 1 advanced solid tumor study. Patients must have advanced or metastatic nectin-4 expressing solid tumors that have progressed following at least one line of therapy or have no other standard therapy with proven clinical benefit

More info (clinicaltrials.gov)

Recruiting now in:

  • London

A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors

Phase 1 advanced solid tumor study. Tumor must have specific genetic mutations (loss-of-function NF2/LATS1/LATS2 genetic alterations or functional YAP/TAZ fusions) and no further standard treatments are available to the patient

More info (clinicaltrials.gov)

Recruiting now in:

  • Manchester

A Phase I/​II Trial of UCB4594 in Participants With Advanced Cancer

Phase 1 & 2, advanced solid tumors for which no conventional therapy is considered appropriate by the Investigator or is declined by the participant

CRUK plain English summary (cancerresearchuk.org)

More info (clinicaltrials.gov)

Recruiting now in:

  • Manchester

A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma

Phase 1 & 2, advanced solid tumor

More info (clinicaltrials.gov)

Recruiting now in:

  • Edinburgh
  • Glasgow
  • Manchester
  • Newcastle
  • Oxford

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

Phase 1, advanced solid tumor

More info (clinicaltrials.gov)

Recruiting now in:

  • Glasgow
  • Leeds
  • London
  • Manchester
  • Newcastle

A Study of AMG 193 in Subjects With Advanced MTAP-null Solid Tumors (MTAP)

Phase 1/1b/2 advanced solid tumor study. Tumors must be CDKN2A null and/or MTAP null and the advanced solid tumor must not be amenable to curative treatment with surgery and/or radiation.

More info (clinicaltrials.gov)

Recruiting now in:

  • London

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Phase 1 advanced solid tumor study. Patients must have advanced or metastatic solid tumors that are not considered appropriate for further standard treatment

More info (clinicaltrials.gov)

Recruiting now in:

  • Glasgow
  • London

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Phase 1, advanced solid tumor

More info (clinicaltrials.gov)

Recruiting now in:

  • London

A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Phase 1 advanced solid tumor study. Tumor must have a known ARID1A mutation (via NGS testing) and disease progression occurred during or following prior chemotherapy approved therapies or for which no standard therapy exists

More info (clinicaltrials.gov)

Recruiting now in:

  • Bath
  • Leicester
  • London
  • Sutton
  • Taunton

A Study of DS-9606a in Patients With Advanced Solid Tumors

Phase 1, advanced solid tumor study. First in human study recruiting multiple solid tumor types that express Claudin-6 (CLDN6)

More info (clinicaltrials.gov)

Recruiting now in:

  • London
  • Sutton

A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3

Phase 1a/b advanced solid tumor study. The FGFR3 gene must be altered and all standard therapies deemed appropriate by the investigator must have already been received or refused by the participant

More info (clinicaltrials.gov)

Recruiting now in:

  • Manchester

A Study of NB003 in Patients With Advanced Malignancies

Phase 1 advanced solid tumor study. Disease must be relapsed or refractory with no available effective therapy and a KIT or PDGFRα gene mutation is present

More info (clinicaltrials.gov)

Recruiting now in:

  • Sutton

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Phase 1, advanced solid tumor

More info (clinicaltrials.gov)

Recruiting now in:

  • London
  • Sutton

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Phase 1 advanced solid tumor study. Patients must be intolerant to, or ineligible for standard treatment.

More info (clinicaltrials.gov)

Recruiting now in:

  • Cambridge
  • London

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Phase 1, advanced solid tumor with a KRAS G12C mutation

More info (clinicaltrials.gov)

Recruiting now in:

  • Birmingham
  • Cardiff
  • London
  • Manchester

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of RO7589831 in Participants With Advanced Solid Tumors

Phase 1 advanced solid tumor study. Tumor must have specific genetic alterations: microsatellite instability (MSI) and/or deficient mismatch repair (dMMR)

More info (clinicaltrials.gov)

Recruiting now in:

  • London
  • Manchester

ALKOVE-1: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation

Phase 1/2 advanced solid tumor study. Tumor must have specific genetic alteration (ALK rearrangement or activating ALK mutation) and patient must have received ≥1 prior systemic anticancer therapy, or no satisfactory standard therapy exists

More info (clinicaltrials.gov)

Recruiting now in:

  • Edinburgh
  • Manchester
  • Sutton

ANV419-001: A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Cancer

Phase 1 First in Human trial for advanced solid tumors in which no further available standard therapy likely to confer clinical benefit

More info (clinicaltrials.gov)

Recruiting now in:

  • Sutton

ARROS-1: A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement

Phase 1 advanced solid tumor study. The metastatic solid tumor must have a specific genetic profile (ROS1 rearrangement)

More info (clinicaltrials.gov)

Recruiting now in:

  • London

Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumours

Phase 1, advanced solid tumor

More info (clinicaltrials.gov)

Recruiting now in:

  • Cambridge

CodeBreak 101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

Phase 1b advanced solid tumor study. Metastatic tumor must have a KRAS p.G12C mutation. Patients will be excluded if brain metastases are present

More info (clinicaltrials.gov)

Recruiting now in:

  • London

DDRiver Solid Tumors 301: M1774 in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors

Phase 1 First in Human: Metastatic disease that is refractory to standard therapy

More info (clinicaltrials.gov)

Recruiting now in:

  • Cambridge
  • Manchester
  • Newcastle
  • Sutton

DETERMINE: Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial

Phase 2 & 3, "umbrella-basket platform trial" including common cancers with rare actionable genomic alterations

More info (clinicaltrials.gov)

Recruiting now in:

  • Belfast
  • Birmingham
  • Bristol
  • Cambridge
  • Cardiff
  • Edinburgh
  • Glasgow
  • Leicester
  • Liverpool
  • London
  • Manchester
  • Newcastle
  • Oxford

Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/​or Metastatic Solid Tumors

Phase 1 & 2 advanced solid tumor study. Further standard of care treatments for the patient must either not exist, are no longer effective, or are not acceptable to them

More info (clinicaltrials.gov)

Recruiting now in:

  • Birmingham

ELUCIDATE: Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors

Phase 1 & 2, advanced solid tumor study. Patients must be HR+ and HER2- and have experienced disease progression with prior treatment that included a CD4/CDK6 inhibitor

More info (clinicaltrials.gov)

Recruiting now in:

  • Glasgow
  • London
  • Manchester
  • Newcastle
  • Oxford

EVICTION: First-in-Human Study of ICT01 in Patients With Advanced Cancer

Phase 1 & 2, relapsed patients not responding to standard treatment who have advanced-stage or recurrent cancer

More info (clinicaltrials.gov)

Recruiting now in:

  • London

First in Human Study of T3P-Y058-739 (T3P)

Phase 1, advanced solid tumor

More info (clinicaltrials.gov)

Recruiting now in:

  • Glasgow
  • Leeds
  • London

First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies

Phase 1/2a, advanced solid tumor

CRUK plain English summary (cancerresearchuk.org)

More info (clinicaltrials.gov)

Recruiting now in:

  • Cambridge
  • London

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Phase 1: advanced solid tumors where curative treatment options have been exhausted

More info (clinicaltrials.gov)

Recruiting now in:

  • Manchester
  • Sutton

GARNET: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Phase 1 first in human advanced solid tumor study. No further standard of care treatments are available to the patient or they would be intolerant to them

More info (clinicaltrials.gov)

Recruiting now in:

  • Aberdeen
  • London
  • Manchester
  • Newcastle

GEN1047 for Solid Tumors - First in Human (FIH) Trial

First In Human, Phase I/IIa trial for advanced solid tumors for which there is no further available standard therapy likely to confer clinical benefit

More info (clinicaltrials.gov)

Recruiting now in:

  • London
  • Manchester

HMBD-001 in Advanced HER3 Positive Solid Tumours

Phase 1 & 2, advanced solid HER3+ tumors, including TNBC

CRUK plain English summary (cancerresearchuk.org)

More info (clinicaltrials.gov)

Recruiting now in:

  • London
  • Oxford

iintune-1: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Phase 1 & 2 advanced solid tumor study. Open to many metastatic solid tumors. Patients must have no standard therapeutic options or are intolerant to these standard options

More info (clinicaltrials.gov)

Recruiting now in:

  • Leeds
  • London
  • Oxford
  • Sutton

Integrated short-term palliative rehabilitation in incurable cancer

Incurable solid tumor. Recruitment is irrespective of timing in relation to any oncology or palliative care treatments

More info (isrctn.com)

Recruiting now in:

  • London

JEWEL-101: Study of XB002 in Subjects With Solid Tumors

Phase 1, Metastatic Solid Tumors - metastatic breast cancer patients must be TNBC or ER+/HR+ & HER2-

More info (clinicaltrials.gov)

Recruiting now in:

  • Cardiff
  • Glasgow
  • Leicester
  • London
  • Newcastle

LIBRETTO-001: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Phase 1, advanced solid tumor & RET Fusion Positive

More info (clinicaltrials.gov)

Recruiting now in:

  • Sutton

MITOPE: Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Patients with malignant pleural effusion from any solid tumor, including secondary cancers

More info (clinicaltrials.gov)

Recruiting now in:

  • Bristol
  • Glasgow
  • Leeds
  • Leicester
  • London
  • Newcastle
  • Oxford
  • Sutton

MK-6482-015: Belzutifan/​MK-6482 for the Treatment of Advanced Cancers (PPGL, pNET, VHL Disease-Associated Tumors, wt GIST) or Solid Tumors With HIF-2α Related Genetic Alterations

Phase 2 advanced solid tumor study. Tumor must have HIF-2α related genetic alterations and the tumor is not amenable to surgery or curative intent treatment

More info (clinicaltrials.gov)

Recruiting now in:

  • Cambridge
  • Glasgow
  • London

MK-7339-002 /​ LYNK-002: Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

Phase 1 study for multiple types of advanced/metastatic cancer. For metastatic breast cancer, patients can't have a germline BRCA mutation

More info (clinicaltrials.gov)

Recruiting now in:

  • Newcastle

NeoRay: [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake

Phase 1/2a: Tumor must be HR+ with ER > 10% of nuclei stain & HER-2 negative including HER-2 low and no standard therapy is available

More info (clinicaltrials.gov)

Recruiting now in:

New Formulation Study of Inupadenant (EOS100850) in Patients With Cancer

Phase 1, advanced solid tumor

More info (clinicaltrials.gov)

Recruiting now in:

  • Sutton

PETRA: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Phase 1 & 2, advanced solid tumor

CRUK plain English summary (cancerresearchuk.org)

More info (clinicaltrials.gov)

Recruiting now in:

  • Cambridge
  • Manchester
  • Oxford
  • Sutton

Phase I Trial of VS-6766 Alone and in Combination With Everolimus (RAF/MEK)

Phase 1, advanced solid tumor

More info (clinicaltrials.gov)

Recruiting now in:

  • London
  • Sutton

Phase Ia, First in Human Open Label Dose Escalation Trial Evaluating Intravenous BI 1703880 in Combination With Intravenous Ezabenlimab for Treatment of Advanced Solid Tumours

Phase 1, advanced solid tumor

More info (clinicaltrials.gov)

Recruiting now in:

  • London
  • Oxford
  • Sutton

PIKASSO-01: A Study of LOXO-783 in Patients With Breast Cancer/​Other Solid Tumors

Phase 1 trial for patients with advanced breast cancer or other solid tumors. Patients must have a PIK3CA mutation and have had 2-5 prior regimens for advanced disease treatment

More info (clinicaltrials.gov)

Recruiting now in:

  • London
  • Sutton

POTENTIA: Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours

Phase 1, advanced solid tumor that is PSMA+

More info (clinicaltrials.gov)

Recruiting now in:

  • London
  • Manchester
  • Sutton

PYNNACLE: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Phase 1/2 study, for patients who have advanced solid metastatic tumors that have a TP53 Y220C mutation

More info (clinicaltrials.gov)

Recruiting now in:

  • London

SABR-COMET-3: Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer

Phase 3, patients must have 1-3 current metastases and a maximum 8 lifetime metastases

More info (clinicaltrials.gov)

Recruiting now in:

  • Aberdeen
  • Edinburgh
  • Glasgow

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Phase 1, advanced solid tumor: PRAME positive tumor

More info (clinicaltrials.gov)

Recruiting now in:

  • Glasgow
  • Liverpool
  • London
  • Manchester
  • Oxford
  • Sutton

Safety and Preliminary Efficacy of BNT314 With or Without an Immune Checkpoint Inhibitor in Cancer Patients With Malignant Solid Tumors

Phase 1 & 2, advanced solid tumor study. For patients whom at the discretion of the investigator there is no available standard therapy likely to confer clinical benefit

More info (clinicaltrials.gov)

Recruiting now in:

  • Manchester
  • Newcastle
  • Sutton

SEACRAFT-1: A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

Phase 1 advanced solid tumor study. Disease must not be responsive to, or eligible for, standard therapy and a RAS Q61X mutation is present. Patients with CNS tumors are not eligible

More info (clinicaltrials.gov)

Recruiting now in:

  • Glasgow
  • London

SPARTA: APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Phase 2 advanced solid tumor study. Multiple cohort types are available and require specific mutations: solid tumors harboring MET amplification or MET fusion or wild-type MET with overexpression of HGF and MET. Standard treatment options must be exhauste

More info (clinicaltrials.gov)

Recruiting now in:

  • London
  • Manchester
  • Sutton

Study of GS-4528 in Adults With Solid Tumors

Phase 1, advanced solid tumor study. Patients have received, been intolerant to, or have been ineligible for all treatment known to confer clinical benefit

More info (clinicaltrials.gov)

Recruiting now in:

  • Sutton

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Phase 1 advanced solid tumor study. Patients must have received, and then progressed, relapsed, or been intolerant to, or ineligible for, at least 1 standard treatment regimen in the advanced or metastatic setting

More info (clinicaltrials.gov)

Recruiting now in:

  • Birmingham
  • Glasgow
  • London
  • Oxford
  • Southampton

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

Phase 1, advanced solid tumor

More info (clinicaltrials.gov)

Recruiting now in:

  • Liverpool
  • London
  • Oxford

Study to Evaluate CCS1477 in Advanced Tumours

Phase 1 & 2, advanced solid tumor

CRUK plain English summary (cancerresearchuk.org)

More info (clinicaltrials.gov)

Recruiting now in:

  • Belfast
  • Birmingham
  • Cambridge
  • Edinburgh
  • Glasgow
  • Leicester
  • Manchester
  • Newcastle
  • Southampton
  • Sutton

Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors

Phase 1 advanced solid tumor study. Tumor must express cadherin-3 and mesothelin and standard of care treatments must have been exhausted

More info (clinicaltrials.gov)

Recruiting now in:

  • London

TARGET National: Tumour Characterisation to Guide Experimental Targeted Therapy

Prospective study that aims to determine the number of patients matched to a trial of an experimental therapeutic agent based on molecular findings from ctDNA or tumor

More info (clinicaltrials.gov)

Recruiting now in:

  • Belfast
  • Birmingham
  • Cambridge
  • Cardiff
  • Edinburgh
  • Glasgow
  • Leeds
  • Leicester
  • Liverpool
  • London
  • Manchester
  • Newcastle
  • Oxford
  • Preston
  • Sheffield
  • Southampton

The first-in-human trial of MDX-124 in patients with advanced cancer

Phase 1 First in Human, TNBC and solid tumor must overexpress ANXA1

More info (isrctn.com)

Recruiting now in:

  • Edinburgh
  • Liverpool
  • Oxford

TRESR: Study of RP-3500, Camonsertib, in Advanced Solid Tumors

Phase 1/2a, advanced solid tumor study. First in human study recruiting multiple solid tumor types that have a ATR inhibitor-sensitizing mutation. Patients current disease must be resistant to standard treatment or be intolerant to standard therapy

More info (clinicaltrials.gov)

Recruiting now in:

  • Manchester

TRIDENT-1: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 advanced solid tumors that have an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement

More info (clinicaltrials.gov)

Recruiting now in:

  • London
  • Manchester
  • Sutton

VELA: Study of BLU-222 in Advanced Solid Tumors

Phase 1/2 trial for advanced solid tumors including metastatic HR+ HER2- breast cancer that has progressed following CDK4/6 inhibitor treatment

More info (clinicaltrials.gov)

Recruiting now in:

  • London

Footnotes for Healthcare Professionals

 The registry was last updated on: 25th August 2024.  

How the registry is complied

The databases used to compile this clinical trial registry are: clinicaltrials.gov & NIHR Be Part of Research.

Only secondary breast cancer clinical trials that are noted as actively recruiting in the UK on ClinicalTrials.gov are listed in this registry. However, there can be a delay in how quickly ClinicalTrials.gov is updated and a study might be listed as actively recruiting, but has already closed to recruitment.    

There is a possibility that other clinical trials might be available due to the speed at which ClinicalTrials.gov is updated by research teams.  

Next steps

You can find out more about each specific trial by clicking its associated study link. Our Patient Trials Advocate (PTA) service is available to conduct a bespoke and detailed clinical trials search. We support patients based in the UK however we can access information on international clinical trials. Patients can self-refer to the service here.

Send feedback on the registry to: clinical.trials@make2ndscount.co.uk

Development of the registry

Make 2nds Count created the registry based on the research findings of a national survey conducted in 2021 that was funded by Make 2nds Count. The study found that secondary breast cancer patients had a lack of information about clinical trials, limited opportunities to discuss trials with their clinical team and many advocated for a patient friendly clinical trial registry specific to secondary breast cancer.

As a charity, Make 2nds Count pioneered the innovative Patient Trials Advocate (PTA) service and this dedicated UK Clinical Trials Registry to address the informational needs raised in the survey, but there is more work to be done. We all share a responsibility in igniting a national conversation about clinical trials.